Aspire Biopharma Holdings (ASBP) Change in Cash (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Change in Cash of $4.9 million for Q1 2026, up 261.39% year-over-year from $1.3 million in Q1 2025, and up 613.9% quarter-over-quarter from -$944367.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Change in Cash (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Change in Cash for 5 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 261.39% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.5 million (up 247.16% YoY), while the FY2025 annual figure was $1.0 million, up 13364.43% from the prior year.
- Change in Cash rose to $4.9 million in Q1 2026 per ASBP's latest filing, from -$944367.0 in the prior quarter.
- Across five years, Change in Cash topped out at $4.9 million in Q1 2026 and bottomed at -$1.1 million in Q2 2025.
- Historically, Change in Cash has averaged $343873.5 across 5 years, with a median of -$27683.0 in 2024.
- On a YoY basis, Change in Cash climbed as much as 56973.59% in 2025 and fell as far as 7216.14% in 2025.
- Aspire Biopharma Holdings' Change in Cash stood at -$35870.0 in 2022, then soared by 99.22% to -$280.0 in 2023, then slumped by 4510.0% to -$12908.0 in 2024, then slumped by 7216.14% to -$944367.0 in 2025, then surged by 613.9% to $4.9 million in 2026.
- Business Quant data shows ASBP's Change in Cash at $4.9 million in Q1 2026, -$944367.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 6.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.31 Mn |
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | -944,367.00 |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | -12,908.00 |
| Sep 30, 2024 | -3,063.00 |
| Jun 30, 2024 | -27,683.00 |
| Mar 31, 2024 | 36,113.00 |
| Dec 31, 2023 | -280.00 |
| Sep 30, 2023 | -124,921.00 |
| Jun 30, 2023 | -189,951.00 |
| Mar 31, 2023 | -182,107.00 |
| Dec 31, 2022 | -35,870.00 |
| Sep 30, 2022 | -46,622.00 |
| Jun 30, 2022 | -38,371.00 |
| Mar 31, 2022 | 618,122.00 |